News

The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer’s disease and mild cognitive impairment. In addition, the

Under the expanded agreement, in addition to commercializing SensiGen’s advanced test for human papillomavirus exclusively on Sequenom’s MassArray platform, SensiGen will also be the exclusive provider of MassArray

Protect sites in the US will serve to provide the FDA with US-specific data on the post-market experience with the Endeavor stent. The US sites will enroll a

Their stake was purchased from Biggar, a charitable foundation that is said to be ThromboGenics’s largest shareholder. Biggar now holds a 9.8% stake in ThromboGenics following this transaction,

The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-4523655 versus laser therapy in 160 diabetic macular edema (DME) patients at multiple centers

Abiomed expects to begin facility preparations immediately and currently anticipates that the first Impella 2.5 cardiac assist device production line will be operational in approximately eighteen months. Abiomed’s

The data also indicated that GGF2 provided more benefit than other neuregulin fragments that were also tested. In preclinical testing, neuregulins have shown the potential to reduce and

Peptimmune’s PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and

The concerned EU member states concluded that the profile of Toctino (alitretinoin) is favorable for use in adults who suffer from severe chronic hand eczema that is unresponsive